NHS Logo
Bedfordshire and Luton Joint Formulary
Bedfordshire Hospitals NHS Foundation Trust
Bedfordshire, Luton and Milton Keynes ICB
Formulary items found
Status Description Section
REDTrastuzumab Herceptin® Malignant disease and immunosuppression, Trastuzumab, 08.01.05
REDTrastuzumab deruxtecan Enhertu®
(100 mg powder for concentrate for solution for infusion) 		Malignant disease and immunosuppression, Other antineoplastic drugs, 08.01.05
REDTrastuzumab emtansine Kadcyla® Malignant disease and immunosuppression, Trastuzumab, 08.01.05
Searchiing the National BNF we found these items - Click button under Local to search local formulary or BNF to view on online BNF.
Local BNF Section
Pertuzumab Pertuzumab With Trastuzumab [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Trastuzumab Trastuzumab [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Trastuzumab Trastuzumab Deruxtecan [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Trastuzumab Trastuzumab Emtansine [Specialist Drug] Malignant Disease, Antibody Responsive Malignancy, Antineoplastic Drugs Monoclonal Antibodies
Selecting a button in the local column will search the local formulary again for the word on the button. Where the button is in outline no local match at drug name level was found.
Links found
NICE TA 632 Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer
NICE TA107: Breast cancer (early) - trastuzumab
NICE TA1112: Trastuzumab deruxtecan for treating hormone receptor-positive HER2-low metastatic breast cancer after 2 or more endocrine treatments (TERMINATED APPRAISAL)
NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
NICE TA34: Breast cancer - trastuzumab
NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
NICE TA612 Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
NICE TA704: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies
NICE TA786 Tucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies
NICE TA862: Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments
NICE TA976: Trastuzumab deruxtecan for treating HER2-mutated advanced non-small-cell lung cancer after platinum-based chemotherapy (TERMINATED APPRAISAL)
NICE TA983: Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinoma - NOT RECOMMENDED
NICE TA992: Trastuzumab deruxtecan for treating HER2-low metastatic or unresectable breast cancer after chemotherapy (NOT RECOMMENDED)